BioCentury
ARTICLE | Company News

Astellas acquires ophthalmic company Quethera

August 17, 2018 5:25 PM UTC

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million).

"This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus area of research as part of the Company’s strategy," Astellas spokesperson Stefanie Prodouz told BioCentury. In May, Astellas President and CEO Kenji Yasukawa laid out the company's plans to shift its R&D strategy that will build clinical programs around biology, disease and modality (see "Astellas Unveils New R&D Strategy")...